Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials : Journal of Immunotherapy

Secondary Logo

Journal Logo

Basic Study

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Nguyen, Thi Thuy*,†; Thanh Nhu, Nguyen*,‡; Tran, Van Khoi*,§; Van Cau, Nguyen; Lin, Chiou-Feng∥,¶,#

Author Information
Journal of Immunotherapy ():10.1097/CJI.0000000000000471, May 23, 2023. | DOI: 10.1097/CJI.0000000000000471

Abstract

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid